Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

Revised Revenue Forecast:
Moderna has lowered its 2025 revenue forecast to $1.5 billion to $2.5 billion, down from the previous estimate of $2.5 billion to $3.5 billion12.

Cost-Cutting Measures:
The company plans to accelerate cost-cutting initiatives, aiming for $1 billion in savings in 2025 and an additional $0.5 billion in 202625.

Market Challenges:
Increasing competition in the COVID-19 vaccine market and falling vaccination rates are major factors contributing to the revised forecast4.

Product Portfolio Expansion:
Moderna is focusing on diversifying its portfolio, targeting ten product approvals by 2027, including in areas such as oncology and rare diseases5.

Financial Projections:
The company expects to end 2025 with approximately $6 billion in cash and investments, down from $9.5 billion at the end of 202415.

Stock Impact:
Moderna's shares have plummeted nearly 20% following the announcement of the revised revenue forecast and expanded cost-cutting measures24.

Sources:

1. https://www.investing.com/news/stock-market-news/moderna-adjusts-2025-revenue-outlook-shares-fall-93CH-3809347

2. https://www.proactiveinvestors.com/companies/news/1064186/moderna-slashes-2025-sales-forecast-shares-sink-1064186.html

4. https://financialbuzz.com/moderna-stock-drops-20-as-2025-outlook-falls-short-of-expectations/

5. https://www.benzinga.com/25/01/42946454/moderna-expects-lower-annual-sales-expands-cost-cutting-initiatives